What's in Tuberculosis Research Centre, India's pipeline?

Tuberculosis Research Centre, India has 4 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Tuberculosis Research Centre, India's portfolio?

Top competitors by shared drug class: All India Institute of Medical Sciences, Bandim Health Project, Beijing Center for Disease Control and Prevention, Bharat Biotech International Limited, Canadian Immunization Research Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tuberculosis-research-centre-india.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Tuberculosis Research Centre, India — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tuberculosis Research Centre, India pipeline: 0 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Didanosine, Lamivudine, Nevirapine	Didanosine, Lamivudine, Nevirapine	phase 3	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase	Infectious Disease / Virology
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	phase 3	Anti-tuberculosis combination therapy	Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)	Infectious Disease
BCG vaccine (Freeze-dried)	BCG vaccine (Freeze-dried)	phase 3	Live attenuated vaccine		Immunology / Infectious Disease
Isoniazid with Ethambutol	Isoniazid with Ethambutol	phase 3	Antituberculous agents	InhA (isoniazid); arabinosyl transferases (ethambutol)	Infectious Disease

Therapeutic area mix

Infectious Disease · 2
Immunology / Infectious Disease · 1
Infectious Disease / Virology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

All India Institute of Medical Sciences · 1 shared drug class
Bandim Health Project · 1 shared drug class
Beijing Center for Disease Control and Prevention · 1 shared drug class
Bharat Biotech International Limited · 1 shared drug class
Canadian Immunization Research Network · 1 shared drug class
Center for Research and Production of Vaccines and Biologicals, Vietnam · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tuberculosis Research Centre, India:

Cite this brief

Drug Landscape (2026). Tuberculosis Research Centre, India — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tuberculosis-research-centre-india. Accessed 2026-05-16.